Are statins right for you? What your blood tests can tell you beyond cholesterol

How statins work and what they target

Statins inhibit HMG-CoA reductase, an enzyme the liver uses to produce cholesterol. By reducing liver cholesterol synthesis, they prompt liver cells to upregulate LDL receptors, pulling more LDL out of circulation. The result is a reduction in LDL cholesterol of 30 to 60 per cent depending on the statin type and dose. Statins also have anti-inflammatory and plaque-stabilising effects that contribute to cardiovascular protection beyond cholesterol reduction alone. Reducing LDL by 1mmol/L through any means is associated with approximately a 22 per cent reduction in cardiovascular events over five years.

Who is prescribed statins in the UK?

NICE guidelines recommend statins for people with an estimated 10-year cardiovascular risk above 10 per cent (assessed using QRISK3), for anyone who has already had a heart attack or stroke, and for people with conditions that carry inherently elevated cardiovascular risk including type 2 diabetes, chronic kidney disease, and familial hypercholesterolaemia. Some people are also prescribed statins when specific lipid markers (LDL above 5.0mmol/L, for example) are sufficiently elevated to warrant treatment regardless of QRISK3 score. The decision involves weighing absolute benefit against individual risk of side effects and the person's preferences, which is why a fuller blood picture can meaningfully inform the conversation.

The limitation of LDL-only assessment

Standard cholesterol panels measure total cholesterol, LDL, HDL, and triglycerides. LDL is the primary target of statin therapy and the marker most commonly used to assess response. The limitation of LDL alone is that it measures the cholesterol content of LDL particles rather than the number of atherogenic particles circulating. Two people with the same LDL reading can have very different cardiovascular risk profiles if one has predominantly large, buoyant LDL particles and the other has small, dense LDL particles. ApoB measures the total number of atherogenic particles across LDL, VLDL, and IDL, and is increasingly recognised as a more accurate predictor of cardiovascular risk in people with insulin resistance, metabolic syndrome, or elevated triglycerides.

A fuller lipid assessment before or alongside the standard cholesterol test adds significantly to the information available for a treatment decision:

LDL cholesterol remains the primary clinical target. A level above 3.0mmol/L in the presence of other cardiovascular risk factors is typically where statin benefit becomes meaningful.

ApoB gives a more precise picture of atherogenic particle burden than LDL alone. People with elevated triglycerides and metabolic syndrome often have high ApoB despite a normal or only moderately elevated LDL, which means their cardiovascular risk is systematically underestimated by LDL-only testing.

Lp(a) is a genetically determined lipoprotein that is largely unaffected by statins but carries significant independent cardiovascular risk. People with elevated Lp(a) have substantially higher risk of heart attack and stroke, and this information changes the conversation about overall risk management even when LDL is treated effectively. Lp(a) is not included in a standard cholesterol test.

CRP measures systemic inflammation, which is an independent cardiovascular risk factor and a target of statins beyond their cholesterol-lowering effect. People with high CRP and normal cholesterol may still benefit from statins, as shown in the JUPITER trial.

Homocysteine is an independent cardiovascular risk marker linked to B vitamin metabolism and methylation. Elevated homocysteine identifies a modifiable risk pathway (B12, folate, B6 optimisation) that statin therapy does not address but that meaningfully contributes to overall cardiovascular risk.

HbA1c is relevant because statins carry a small but real risk of raising blood glucose, particularly in people who are already insulin resistant or have pre-diabetes. Knowing your baseline HbA1c before starting statins allows monitoring of this effect over time.

Liver function and safety monitoring

Statins are processed by the liver, and in approximately 1 in 1,000 people they cause a clinically significant rise in liver enzymes. NICE recommends a liver function test (measuring ALT) at baseline, at 3 months, and at 12 months after starting a statin or increasing the dose. An ALT above three times the upper limit of normal warrants dose reduction or switching to a different statin. For most people on stable doses, annual monitoring is sufficient, but people who drink alcohol, take other liver-processed medications, or have pre-existing liver conditions benefit from more frequent assessment.

ALT (alanine aminotransferase) is the most relevant liver marker for statin monitoring. It rises when liver cells are under stress and is the standard first indicator of statin-related hepatotoxicity.

AST (aspartate aminotransferase) provides additional liver context and is sometimes measured alongside ALT, particularly when ALT is borderline elevated.

Muscle-related markers and symptoms

Statin-associated muscle symptoms (SAMS) affect between 5 and 20 per cent of people on statins in clinical practice, ranging from mild muscle aches to the rare but serious condition of rhabdomyolysis (severe muscle breakdown). The underlying mechanism involves statins inhibiting not only cholesterol synthesis but also the production of coenzyme Q10 (CoQ10), a compound essential for mitochondrial energy production in muscle cells. Whether CoQ10 depletion is the primary mechanism of SAMS remains debated, but statins consistently reduce circulating CoQ10 levels and impair mitochondrial function in some individuals.

CK (creatine kinase) is measured when muscle symptoms are present. A CK above 10 times the upper limit of normal warrants statin discontinuation. Mild CK elevation (1 to 3 times the upper limit) in the absence of significant symptoms can be monitored while lifestyle factors (dehydration, exercise, alcohol) are addressed.

Blood glucose and diabetes risk

Statins increase the risk of new-onset type 2 diabetes by approximately 10 per cent in people at intermediate metabolic risk, primarily by impairing insulin secretion from pancreatic beta cells and worsening insulin sensitivity in peripheral tissues. This effect is dose-dependent and most pronounced with higher-intensity statins (atorvastatin, rosuvastatin) at higher doses. For people who are already insulin resistant or have pre-diabetes, monitoring HbA1c annually while on statins allows early identification of blood glucose deterioration before it reaches diabetes thresholds.

HbA1c is the appropriate marker for monitoring statin-related blood glucose effects over time. NICE recommends annual HbA1c monitoring for people on statins.

If you are on statins and experiencing muscle aches, fatigue, or other symptoms you suspect may be medication-related, a comprehensive blood panel can help determine whether these markers reflect a physiological pattern worth discussing with your GP, whether dose adjustment may be appropriate, and whether any modifiable factors (vitamin D deficiency, thyroid dysfunction, CoQ10 depletion) might be contributing independently of the statin itself.

Dietary approaches that work alongside statin therapy

Statins are most effective when combined with dietary changes that independently reduce cardiovascular risk. A Mediterranean-pattern diet (high in olive oil, oily fish, legumes, vegetables, nuts, and whole grains) reduces cardiovascular risk through mechanisms that complement rather than duplicate statin action, including anti-inflammatory effects, improved endothelial function, and reduced triglycerides. Reducing refined carbohydrates and ultra-processed foods addresses insulin resistance, which statins do not directly treat and which contributes substantially to overall cardiovascular risk.

Exercise, muscle health, and statin tolerance

Regular aerobic exercise reduces cardiovascular risk through multiple pathways including improved endothelial function, lower blood pressure, and improved lipid profiles. Resistance training also improves insulin sensitivity, which matters because statins can marginally worsen this. Practically, some people on statins find that high-intensity exercise worsens muscle symptoms (SAMS): if this is occurring, discussing dose reduction, switching to a different statin, or taking a two-week statin holiday to assess whether symptoms resolve may be informative. Exercising at a lower intensity consistently is more sustainable and produces meaningful cardiovascular benefit without exacerbating SAMS.

Sleep, inflammation, and cardiovascular risk

Chronic sleep restriction independently raises CRP and increases cardiovascular risk through mechanisms that statins do not address. Achieving consistently seven to nine hours of good-quality sleep lowers CRP, improves HDL metabolism, and reduces the insulin resistance that underlies much of the residual cardiovascular risk experienced by people already on statins. For people with sleep apnoea specifically, treating this condition has been shown to reduce CRP, blood pressure, and cardiovascular event risk in ways that complement lipid-lowering therapy.

Vitamin D, B12, and B vitamins for residual risk

Several micronutrient deficiencies contribute to cardiovascular risk independently of cholesterol levels. Vitamin D deficiency is associated with endothelial dysfunction, hypertension, and increased inflammatory burden. B12 and folate deficiency drive elevated homocysteine, an independent cardiovascular risk factor. Testing these alongside a full lipid panel identifies modifiable contributing factors that statin therapy leaves unaddressed.